Amgen, Inc. (NASDAQ: AMGN) stock fell over 1.7% on 30 th October, 2019 (as of 9:59 am GMT-4; Source: Google finance) post third quarter of FY 19 performance. The company had reported 3 percent fall in the adjusted revenue to $5.74 billion in the third quarter of FY 19. Worldwide product sales was at $5.5 billion for the quarter, that had declined 1% year-over-year as growth for the newer products was slightly outpaced by declines in the mature brands impacted by increasing competition due to patent expirations. Other revenues have also fallen by $120 million year-over-year due to a prior year milestone payment.